打开APP

诺华在欧洲推出Lucentis预充注射剂

  1. Lucentis
  2. 诺华
  3. 诺适得
  4. 雷珠单抗

来源:生物谷 2014-03-21 09:09

诺华在德国推出眼科药物Lucentis预充注射剂,并将于2014年在其他欧洲市场上市。该药已获批用于多种眼科疾病的治疗。

2014年3月20日讯 /生物谷BIOON/ --诺华(Novartis)3月20日宣布,在德国推出诺适得(Lucentis,通用名:雷珠单抗,ranibizumab)预充注射剂,该产品将于2014年在欧洲其他市场上市。预充式注射器配方,专门设计用于眼内注射,以加强患者的安全和临床医生的便利。

Lucentis预充式注射剂诸多优势,如可提供更高的剂量准确性和更方便的治疗过程,同时,不可缩回式柱塞可降低非无菌条件下不良事件的风险。这些特性有望减少治疗等待时间,改善患者的治疗经历。

Lucentis是一种人源化的治疗性抗体片段,旨在阻断所有生物活性形式的血管内皮细胞生长因子A(VEGF-A),该因子的水平在湿性AMD和其他眼科疾病(如糖尿病性黄斑水肿(DME)、视网膜静脉阻塞(RVO))升高。Lucentis专门设计用于眼部,使系统性暴露(systemic exposure)最小化。

目前,Lucentis已获100多个国家批准,用于治疗湿性年龄相关性黄斑变性(wet-AMD)、糖尿病性黄斑水肿(DME)所致的视力损害、视网膜静脉阻塞(RVO)继发黄斑水肿(macular edema)所致的视力损害。此外,Lucentis已获40多个国家批准,用于病理性近视继发脉络膜新生血管(myopic CNV)引发的视力损害。

Lucentis于2006年上市,由罗氏(Roche)旗下基因泰克(Genentech)和诺华合作开发,是诺华的一个重要产品,罗氏拥有Lucentis在美国的商业化权利,诺华则拥有该药在美国以外国家和地区的独家权利。(生物谷Bioon.com)

英文原文:Novartis Launches Lucentis Prefilled Syringe in Europe

3/20/2014 2:32 AM ET
Novartis AG (NVS: Quote) Thursday announced the launch of the Lucentis or ranibizumab pre-filled syringe in Germany, with other markets to follow throughout 2014.

The Lucentis pre-filled syringe or PFS, which received European approval in October 2013, is a new way of administering Lucentis that is specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.

David Epstein, Division Head, Novartis Pharmaceuticals, said, ''We are pleased to be able to offer a better way to accurately and safely administer Lucentis in the eye. Lucentis PFS brings convenience, safety, and the potential for improved efficiency and dose accuracy to both retinal specialists and patients."

The Lucentis PFS has been specifically designed to reduce the risk of adverse events to patients and to enhance the treatment process in the clinic. This new injection technology offers the potential for improved safety for patients through a reduction in non-sterile preparatory steps and the inclusion of more safety features, such as a non-retractable plunger. Moreover, greater dose accuracy is possible through design features such as a smaller syringe barrel.

According to the company, these features combined may equate to reduced waiting times and thereby improve the patient treatment experience.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->